adenyl cyclase Inhibitors
1 drugsAbout adenyl cyclase
Adenylyl cyclase is an enzyme that catalyzes the synthesis of cyclic AMP (cAMP) from ATP, a crucial second messenger regulating numerous physiological processes.
Adenylyl cyclase is a drug target in respiratory diseases, but there is currently no genetic evidence data available linking it to specific diseases.
There is one FDA-approved drug, SEREVENT (GSK), a small molecule targeting adenyl cyclase for respiratory indications since 1994.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top adenyl cyclase Drugs
GSK is the only company with an approved drug targeting adenyl cyclase.
Low market concentration indicates a potential opportunity for new entrants in this therapeutic area.
adenyl cyclase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets adenyl cyclase, using small molecule modality.
The lack of modality diversity suggests a whitespace opportunity for novel biologics targeting adenyl cyclase.
adenyl cyclase Clinical Trials 47 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 11 | 10 | 1 | 0 | 91% |
| Phase 2 | 8 | 8 | 0 | 0 | 100% |
| Phase 3 | 13 | 10 | 2 | 1 | 83% |
| Phase 4 | 15 | 14 | 1 | 0 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
adenyl cyclase Drug Approval Timeline (1994 - 1994)
The first and only drug, SEREVENT, was approved in 1994.
The lack of recent approvals suggests potential saturation or renewed opportunity for innovation in adenyl cyclase targeting.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 30 clinical trials targeting adenyl cyclase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities